다가 백신 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global multivalent vaccines market size is expected to reach USD 23.30 Billion in 2034 from USD 9.69 Billion in 2025, growing at a CAGR of 10.24 during 2026-2034.This market is experiencing robust growth as healthcare systems prioritize efficient disease prevention and broad-spectrum immunization strategies. Multivalent vaccines provide protection against multiple strains or diseases within a single formulation, improving vaccination coverage and convenience. Rising prevalence of infectious diseases and increasing immunization programs are major factors driving market expansion. Government support and global public health initiatives are further contributing to demand growth.

Pharmaceutical companies are investing heavily in vaccine research and development to enhance efficacy, safety, and disease coverage. Advances in biotechnology and immunology are enabling the creation of innovative vaccine formulations targeting multiple pathogens. Growing awareness regarding preventive healthcare and expanding vaccination campaigns are supporting widespread adoption. Increasing pediatric and adult immunization efforts are also strengthening market prospects.

Future opportunities are expected to emerge from ongoing vaccine innovation and expanding global healthcare access. Development of next-generation multivalent vaccines for emerging diseases will create substantial growth potential. Investments in manufacturing capacity and distribution infrastructure will improve availability across regions. Long-term market growth will be supported by continued focus on disease prevention and public health preparedness.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Recombinant Vaccines

By Disease

• Influenza
• Pneumonia
• Hepatitis
• Meningitis
• Rotavirus

By Route of Administration

• Oral
• Injectable

By Age Group

• Pediatrics
• Adults
• Geriatrics

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Moderna Inc., BioNTech SE, Zydus Lifesciences Limited, CSL Seqirus, Sinovac Biotech Ltd., GC Biopharma Corp., Emergent BioSolutions Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MULTIVALENT VACCINES MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Conjugate Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Inactivated and Subunit Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Live Attenuated Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.5. Toxoid Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.6. Recombinant Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL MULTIVALENT VACCINES MARKET: BY DISEASE 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Disease
• 5.2. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Pneumonia Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Hepatitis Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.5. Meningitis Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.6. Rotavirus Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL MULTIVALENT VACCINES MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL MULTIVALENT VACCINES MARKET: BY AGE GROUP 2022-2034 (USD MN and Million Doses)

• 7.1. Market Analysis, Insights and Forecast Age Group
• 7.2. Pediatrics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.4. Geriatrics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL MULTIVALENT VACCINES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 9. GLOBAL MULTIVALENT VACCINES MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.2.1 By Type
  • 9.2.2 By Disease
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Age Group
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.3.1 By Type
  • 9.3.2 By Disease
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Age Group
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.4.1 By Type
  • 9.4.2 By Disease
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Age Group
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.5.1 By Type
  • 9.5.2 By Disease
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Age Group
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.6.1 By Type
  • 9.6.2 By Disease
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Age Group
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL MULTIVALENT VACCINES INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Pfizer Inc
  • 11.2.2 Merck & Co. Inc
  • 11.2.3 Sanofi SA
  • 11.2.4 AstraZeneca Plc
  • 11.2.5 Abbott Laboratories
  • 11.2.6 Novartis AG
  • 11.2.7 GlaxoSmithKline Plc
  • 11.2.8 Boehringer Ingelheim International GmbH
  • 11.2.9 Moderna Inc
  • 11.2.10 BioNTech SE
  • 11.2.11 Zydus Lifesciences Limited
  • 11.2.12 CSL Seqirus
  • 11.2.13 Sinovac Biotech Ltd
  • 11.2.14 GC Biopharma Corp
  • 11.2.15 Emergent BioSolutions Inc